{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T18:11:05Z","timestamp":1778004665157,"version":"3.51.4"},"reference-count":26,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2025,10,8]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Schistosomiasis-associated pulmonary arterial hypertension (Sch-PAH) is one of the most prevalent forms of PAH in Brazil. However, no prospective data are available for evaluating the efficacy of PAH drugs in the treatment of Sch-PAH. Does selexipag improve pulmonary vascular resistance (PVR) in Sch-PAH patients?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The SELSCH study was a single-centre, single-arm, open-label prospective study with the aim of evaluating selexipag for the treatment of Sch-PAH. The primary end-point was a reduction in PVR at week 16.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      20 Sch-PAH patients completed the SELSCH study. 20% (n=4) of them used sildenafil as baseline monotherapy, 10% (n=2) used an endothelin receptor antagonist (ERA) and 65% (n=13) of the patients used combination therapy (sildenafil+ERA) before the addition of selexipag. One patient (5%) started selexipag as PAH monotherapy. Selexipag reduced PVR from 9.4\u00b13.93 to 7.75\u00b13.81\u2005WU (p=0.048) and improved World Health Organization Functional Class (p=0.021). There was an increase in cardiac index (from 2.5\u00b10.86 to 2.9\u00b10.67\u2005L\u00b7min\n                      <jats:sup>\u22121<\/jats:sup>\n                      \u00b7m\n                      <jats:sup>\u22122<\/jats:sup>\n                      ; p=0.18), without statistical significance. No differences in right atrial pressure, central venous oxygenation, mean pulmonary arterial pressure, 6-min walk test distance or brain natriuretic peptide levels, or in the COMPERA 2.0 risk stratification, were observed. 40% of patients reported headache or extremity\/jaw pain of mild severity and 10% reported pain of moderate intensity. 40% of patients reported mild gastrointestinal effects. Most of the side-effects occurred only during the early days of the titration period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Selexipag was effective in the treatment of the 20 Sch-PAH studied patients since it significantly reduced PVR by 18%. Selexipag was well tolerated, despite the occurrence of side-effects during the titration phase. The SELSCH study is the first to demonstrate the prospective efficacy of specific PAH therapy in patients with schistosomiasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.00959-2025","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:50:14Z","timestamp":1761843014000},"page":"00959-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Selexipag for the treatment of schistosomiasis-associated pulmonary arterial hypertension: the SELSCH study"],"prefix":"10.1183","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4912-021X","authenticated-orcid":false,"given":"Caio Julio Cesar","family":"dos Santos Fernandes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Hoette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Le\u00f4nidas","family":"Alves-Jr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2199-9525","authenticated-orcid":false,"given":"William","family":"Salibe-Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Vianna Poyares","family":"Jardim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogerio","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"2026050510160690000_12.2.00959-2025.1","doi-asserted-by":"crossref","first-page":"750","DOI":"10.36660\/abc.20200702","article-title":"Update on the treatment of pulmonary arterial hypertension","volume":"117","author":"Fernandes","year":"2021","journal-title":"Arq Bras Cardiol"},{"key":"2026050510160690000_12.2.00959-2025.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879-2022"},{"key":"2026050510160690000_12.2.00959-2025.3","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1233314"},{"key":"2026050510160690000_12.2.00959-2025.4","first-page":"419","article-title":"Pulmonary hypertension in general cardiology practice","volume":"113","author":"Calderaro","year":"2019","journal-title":"Arq Bras Cardiol"},{"key":"2026050510160690000_12.2.00959-2025.5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00307-2018"},{"key":"2026050510160690000_12.2.00959-2025.6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1742-1241.2009.02234.x","article-title":"Schistosomiasis associated pulmonary hypertension","volume":"165","author":"Hovnanian","year":"2010","journal-title":"Int J Clin Pract Suppl"},{"key":"2026050510160690000_12.2.00959-2025.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra012396"},{"key":"2026050510160690000_12.2.00959-2025.8","doi-asserted-by":"publisher","DOI":"10.1586\/ers.11.58"},{"key":"2026050510160690000_12.2.00959-2025.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.803221"},{"key":"2026050510160690000_12.2.00959-2025.10","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-1036"},{"key":"2026050510160690000_12.2.00959-2025.11","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000300"},{"key":"2026050510160690000_12.2.00959-2025.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.03.065"},{"key":"2026050510160690000_12.2.00959-2025.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.03.540"},{"key":"2026050510160690000_12.2.00959-2025.14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MCP.0000000000000086","article-title":"Goal-oriented treatment of pulmonary arterial hypertension","volume":"20","author":"Jardim","year":"2014","journal-title":"Curr Opin Pulm Med"},{"key":"2026050510160690000_12.2.00959-2025.15","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-0483"},{"key":"2026050510160690000_12.2.00959-2025.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503184"},{"key":"2026050510160690000_12.2.00959-2025.17","first-page":"1448","article-title":"Declaration of Helsinki (1964)","volume":"313","year":"1996","journal-title":"BMJ"},{"key":"2026050510160690000_12.2.00959-2025.18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.18977"},{"key":"2026050510160690000_12.2.00959-2025.19","unstructured":"European Medicines Agency . International Council on Harmonisation Guideline for Good Clinical Practice. London, European Medicines Agency, 2002."},{"key":"2026050510160690000_12.2.00959-2025.20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12890-015-0115-y","article-title":"Pulmonary artery enlargement in schistosomiasis associated pulmonary arterial hypertension","volume":"15","author":"Hoette","year":"2015","journal-title":"BMC Pulm Med"},{"key":"2026050510160690000_12.2.00959-2025.21","doi-asserted-by":"crossref","first-page":"2102311","DOI":"10.1183\/13993003.02311-2021","article-title":"COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension","volume":"60","author":"Hoeper","year":"2022","journal-title":"Eur Respir J"},{"key":"2026050510160690000_12.2.00959-2025.22","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s12325-023-02730-8","article-title":"Real-world management of patients with pulmonary arterial hypertension: insights from EXPOSURE","volume":"41","author":"Muller","year":"2024","journal-title":"Adv Ther"},{"key":"2026050510160690000_12.2.00959-2025.23","doi-asserted-by":"publisher","DOI":"10.1002\/path.1700460302"},{"key":"2026050510160690000_12.2.00959-2025.24","doi-asserted-by":"publisher","DOI":"10.1590\/S0066-782X2012005000071"},{"key":"2026050510160690000_12.2.00959-2025.25","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00137511"},{"key":"2026050510160690000_12.2.00959-2025.26","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.healun.2021.01.006","article-title":"Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE","volume":"40","author":"Kim","year":"2021","journal-title":"J Heart Lung Transplant"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00959-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:17:01Z","timestamp":1778001421000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00959-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4,29]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1183\/23120541.00959-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00959-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]}}}